| Host: |
E. coli |
| Reactivity: |
SARS-CoV-2 |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-SARS-CoV-2 3C-likease-N-His&Avi protein was developed from e. coli and has a target region of N-His&Avi. For use in research applications. |
| Formulation: |
Supplied as a 0.22 Mu m filtered solution in 20mM HEPES, 120mM NaCl, 10% Glycerol, 2mM TCEP, pH7.4Contact us for customized product form or formulation. |
| Immunogen Region: |
Ser1-Gln306 |
| Immunogen: |
Recombinant SARS-CoV-2 (2019-nCoV) 3C-like Proteinase is produced by E. coli expression system. The target protein is expressed with sequence (Ser1-Gln306) of SARS-COV-2 (2019-nCoV) 3C-like Proteinase (Accession #YP_009725301.1) fused with an initial |
| Background | Recombinant SARS-CoV-2 (2019-nCoV) 3C-like Proteinase is produced by E. coli expression system. The target protein is expressed with sequence (Ser1-Gln306) of SARS-COV-2 (2019-nCoV) 3C-like Proteinase (Accession #YP_009725301.1) fused with an initial Met, a 6×His, Avi tag at the N-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
